Company intelligence / Profile preview

Novascope

Ownership: Private
Development stage: Other

Overview

Novascope is a pioneering biotech company founded in 2022 that develops advanced diagnostic technologies integrating biology with semiconductor technology. Their flagship platforms—BioFET and BCR—enable rapid, accurate detection of critical biomarkers for early diagnosis in neurology, oncology, and sepsis. The company collaborates with global pharmaceutical leaders and research institutions to accelerate clinical adoption of its technologies.

Therapeutic areas: OncologyNeurologyInfectious Diseases
Modalities: DeviceDiagnostic platform
Industry: Molecular Diagnostics

Partnerships

Collaborations with global pharmaceutical leaders and research institutions are mentioned but not specifically named.

Beyond the preview

Go deeper on Novascope.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novascope.

Explore the full profile